Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-β 2-glycoprotein-I antibodies

Revista de Investigacion Clinica

Volumn 57, Issue 4, 2005, Pages 563-571

  Viveros, Martha E ^b   Cabiedes, Javier ^a   Reyes, Elba ^b   Carbal, Antonio R ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Activated protein C resistance; Anti 2 glycoprotein I antibodies; Antiphospholipid antibodies; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; POLYMERASE CHAIN REACTION; THROMBOPHILIA; THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR V; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PLASMA; PLASTICS; PROTHROMBIN TIME; THROMBOPHILIA; THROMBOSIS;

EID: 27844537419     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Alarcón-Segovia D, Delezé M, Oria CV, Sánchez-Guerrero J, Gómez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-65.
2. Alarcón-Segovia D, Sánchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482-8.
3. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin S, Barquinero J et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366-74.
4. Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989; 48: 362-7.
5. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al. Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
6. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, Van Breda-Vriesmen PJC et al. Anticardiolipin antibodies (ACA) are directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
7. 2-Glycoprotein I (apolipoprotein H). Proc Natl Acad Sci (USA) 1990; 87: 4120-4.
8. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa T, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease (Letter). Lancet 1990; 336: 177-8.
9. 2-glycoprotien I cofactors for antiphospholipid antibodies. Lupus 1996; 5(5): 388-92.
10. Sugi T, Mcintyre, JA. Autoantibodies to phosphatydilethanolamine (PE) recognize a kininogen-PE complex. Blood 1995; 86: 3083-9.
11. Ruíz-Argüelles A, Vázquez-Prado J, Delezé M, Pérez-Romano B, Drenkard C, Alarcón-Segovia D, et al. Presence of serum antibodies to coagulation protein C in patients with systemic lupus erythematosus is not associated with antigenic or functional protein C deficiencies. Am J Hematol 1993; 44: 58-9.
12. Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M. Antiannexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 1994; 47(1): 56-8.
13. 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-91.
14. Nimpf J, Bevers EM, Bomans PHH. Prothrombinase activity of human platelets is inhibited by β2- Glycoprotein I. Biochem Biophys Acta 1996; 884: 142-9.
15. 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-906.
16. Alarcón-Segovia D, Cabral AR. The antiphospholipid antibody syndrome: clinical and serological aspects. In: Alarcón GS, Catoggio LJ, editors. Balliéres' Clinical Rheumatology. London: Bailliere Tindall; 2000, p. 139-50.
17. Brandt JT. Antibodies to β2-glycoprotein I inhibit phospholipid dependent coagulation reactions. Thromb Haemost 1993; 70: 598-602.
18. Roubey RAS, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2-glycoprotein I. J Clin Invest 1992; 90: 1100-04.
19. Galli M, Ruggeri L, Barbui T. Differential effects of anti-β2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated Protein C. Blood 1998; 91: 1999-2004.
20. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulant and other "antiphospholipid" autoantibodies. Blood 1994; 84: 2854-67.
21. Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmunity 2000; 15: 163-72.
22. 2 glycoprotein I antibodies. Blood Coagul Fibrinol 1996; 7: 702-04.
23. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
24. 2-glycoprotein-I in the serum of patients with primary antiphospholipid syndrome. J Rheumatol 1995; 22: 1894-8.
25. Galli M, Luciani D, Bertolini G, Barbui T. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.
26. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
27. Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA). Standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-45.
28. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1-6.
29. 2-glycoprotein in the rat: isolation from serum and demonstration in lipoprotein densitiy fractions. J Biochem 1980; 11: 265-70.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
31. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of protein from SDS and acid/urea polyacrylamide gels to nitrocellulose sheets: procedure and some applications. PNAS 1979; 76: 4350-4.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
33. Bertina RM. Laboratory diagnosis of resistance to activated protein C (APC-resistance). Thromb Haemost 1997; 78: 478-82.
34. Benattar N, Schved JF, Biron-Andréani C. A new dilution for the modified APTT-based assay for activated protein C resistance: improvement of the reliability in patients with lupus anticoagulant. Thromb Haemost 2000; 83: 967-8.
35. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
36. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the Factor V Leiden Arg 506-Gln mutation. Blood Coag Fibrinol 2001; 6: 245-8.
37. Jacobsen M, Barna-Cler L, Triplett DA, Wisloff F. The evaluation of clotting times in the laboratory detection of lupus anticoagulants. Thromb Res 2001; 104: 275-82.
38. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Hematol 1990; 76: 101-7.
39. Bokarewa MI, Blomback N, Rosen S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coag Fibrinol 1994; 5: 37.
40. Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada KI et al. β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999; 42: 167-74.
41. Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, et al. Anti-β2-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipids. J Clin Invest 2003; 99: 2260-8.
42. Galli M, Finazzi G, Norbis F, Marchioli R, Barbui T. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999; 81(5): 695-700.
43. Hwang KK, Yang CD, Yan W, Gorssman J, Hahn B, Chen PP. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003; 48: 1622-30.
44. Ruíz-Argüelles GJ, Garcés-Eisele J, Alarcón-Segovia D. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coag Fibrinol 1996; 7: 344-8.
45. Davies KA, Ireland H, Athanassiou P, Lane D, Walport MJ. Factor V Leiden mutation and venous thrombosis (Letter to the Editor). Lancet 1995; 345: 132-3.
46. Simantov R, Lo S, Salmon JE. Factor V Leiden increases the risk of trombosis in patients with antiphospholipid antibodies. Thromb Res 1996; 84: 523-7.
47. Ruiz-Argüelles GJ, González-Estrada S, Garcés-Eisele J, Ruiz-Argüelles A. Primary thrombophilia in Mexico II: A prospective study. Am J Hematol 1999; 60: 1-5.
48. Ruiz-Argüelles GJ, Poblete-Naredo I, Reyes-Núñez V, Garcés-Eisele J, López-Martínez B, Gómez-Rangel J. Primary thrombophilia in Mexico IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients. Rev Invest Clin 2004; 56: 600-4.
49. 2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Scand J Rheumatol 1999; 28: 344-51.
50. Arvieux J, Roussel B, Ponard D, Colomb MG. IgG2 subclass restriction of anti-β2 glycoprotein 1 antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310-5.
51. 2-glycoprotein-1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology 2001; 40: 1026-32.
52. Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995; 73: 29-34.
53. 2glycoprotein I in patients with antiphospholipid syndrome. J Clin Lab Anal 1998; 12: 293-7.
54. Potzsch B, Kawamura H, Preissner KT, Schmidt M, Seeling C, Muller-Berghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995; 125: 16-7.